secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioCardia, Inc. (BCDA)
CIK:        0000925741
Form:       8-K
Filed at:   2025-03-31T23:59:59+00:00
Accession:  0001437749-25-009978
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCardia Phase 3 CardiAMP-HF shows survival benefit, MACCE reduction at 2 years; primary endpoint not met
--------------------------------------------------------------------------------

- Primary composite efficacy endpoint did not reach statistical significance in overall 115-patient trial.
- In all treated patients: 20.9% relative risk reduction in heart death equivalents; 44.6% reduction in non-fatal MACCE.
- Patients with elevated NTproBNP (50% of cohort) showed statistically significant composite of survival, MACCE, and QOL.
- Treated subgroup (elevated NTproBNP) saw 47% relative risk reduction in heart death equivalents and 10.5-point MLHFQ improvement.
- Company plans to discuss results with FDA and PMDA to align on regulatory pathway for this Breakthrough Therapy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/925741/000143774925009978/0001437749-25-009978-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/925741/000143774925009978/bcda20250330_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-009978

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer